Vanda Pharmaceuticals Inc. (LON: 0LKB)

Market Cap	205.94M
Revenue (ttm)	142.40M
Net Income (ttm)	-12.23M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,442
Average Volume	1,740
Open	4.510
Previous Close	4.425
Day's Range	4.405 - 4.538
52-Week Range	2.816 - 5.390
Beta	n/a
RSI	41.70
Earnings Date	Feb 7, 2025

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 203
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LKB

Financial Performance

In 2023, Vanda Pharmaceuticals's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.

Financial numbers in USD